Michael P. Silvon
Directeur/Bestuurslid bij Chronic Airway Therapeutics
Profiel
Michael P.
Silvon is currently a Director at Chronic Airway Therapeutics.
Previously, he held the position of Vice President-Planning & Development at Inotiv, Inc. He was also the General Manager at BAS Evansville, Inc. from 2000 to 2002.
Additionally, he served as Vice President-Sales & Marketing at Hi-Port, Inc. and as Regional Business Manager-Americas-Fine Chemicals at Zeneca, Inc. Silvon received his undergraduate degree from Loyola University of Chicago, his MBA from Sacred Heart University, Inc., and his doctorate from the University of Vermont.
Actieve functies van Michael P. Silvon
| Bedrijven | Functie | Begin |
|---|---|---|
Chronic Airway Therapeutics
 Chronic Airway Therapeutics BiotechnologyHealth Technology Chronic Airway Therapeutics develops treatments for chronic respiratory diseases. The private company is based in Kew East, Australia. The CEO of the Australian company is Mitchell Glass. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Michael P. Silvon
| Bedrijven | Functie | Einde |
|---|---|---|
| BAS Evansville, Inc. | Corporate Officer/Principal | 01-01-2002 |
| Zeneca, Inc. | Corporate Officer/Principal | - |
| Hi-Port, Inc. | Verkoop & Marketing | - |
| INOTIV, INC. | Corporate Officer/Principal | - |
Opleiding van Michael P. Silvon
| Loyola University of Chicago | Undergraduate Degree |
| Sacred Heart University, Inc. | Masters Business Admin |
| University of Vermont | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| INOTIV, INC. | Commercial Services |
| Bedrijven in privébezit | 4 |
|---|---|
| BAS Evansville, Inc. | |
| Hi-Port, Inc. | |
| Zeneca, Inc. | |
Chronic Airway Therapeutics
Chronic Airway Therapeutics BiotechnologyHealth Technology Chronic Airway Therapeutics develops treatments for chronic respiratory diseases. The private company is based in Kew East, Australia. The CEO of the Australian company is Mitchell Glass. | Health Technology |
